The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | ADAPT: evaluating the use of hydroxyurea to reduce transfusion in Ugandan children with SCD
Alexandra Power-Hays, MD, Cincinnati Children’s, Cincinnati, OH, shares insights into the ADAPT trial (NCT05662098), which is investigating the reduction in blood transfusions with the use of hydroxyurea in Ugandan children with sickle cell disease (SCD), as well as the feasibility of pharmacokinetic-guided dosing of this agent. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
